There’s no doubt about it: marijuana is fast becoming big business. Some thirty U.S. States, and the District of Columbia, currently allow marijuana use in some form or another. The government’s shift regarding marijuana use compared to just a decade ago has been unprecedented and shows no signs of stopping. Our neighbor to the north, Canada, is poised to legalize its recreational use on a national basis. A world where recreational use by adults in the U.S. is not hard to imagine if given enough time.
Taking advantage of this are the “Pot Stocks” companies that are at the forefront of this budding industry. Within this group, some sub-industries focus on cannabis’ medicinal use, while some focus on the recreational use of cannabis derivatives, the most common of which is cannabidiol oil (CBD). CBD is legal at the federal level due to its non-psychoactive properties and companies that focus on this segment of the market are seeing record growth. One such company, Ubiquitech Software Corp. (OTCMKTS:UBQU) via its HempLife Today subsidiary, seems poised to build on its already impressive growth and reward its investors in the process.
What exactly is CBD?
Cannabis has numerous uses. Modern applications are just now coming into play as legal use has increased. One such use, the consumption of an extract known as CBD is already legitimate at the Federal level in the United States. Since CBD is non-psychoactive, the government has seen no reason to regulate it as heavily. Its legality and effectiveness for medicinal and relaxation purposes have yielded a booming industry comprised of everything from cooking oils to edible consumer products.
According to the Hemp Business Journal, the CBD market alone will come to some $450 million—representing a staggering 50 percent annual growth rate from its current estimated size. And this says nothing of the optionality that companies operating in this space have as leaders in the cannabis market. This industry is expected to have had a $31.2-billion economic impact in 2017 by New Frontier Data.
Enter HempLife Today
Last year Forbes ranked what it deemed to be the top five CBD suppliers in the burgeoning CBD market. One of the companies that happened to be on the list was HempLife Today, Ubiquitech Software’s primary subsidiary. Forbes no doubt included HempLife in their list because of its status as a leader in the space: it is a well-respected manufacturer of everything from skin salves to vaping oils and gel caps. It sells its suite of products under the CannazALL brand. Financial results in recent years have been encouraging: Recent results for the first nine months of 2017 have been even better. In a press release put out on October 17, 2017, Ubiquitech announced that HempLife had seen Q3 revenues rise 25 percent year-over-year to $1.13 million and that revenues for FY 2017 had risen a staggering 44 percent.
All the better, the company’s growth might be about to enter the stratosphere. On February 8, 2018, the company announced that it was taking further steps to expand its product lineup through the addition of CannazALL CBD Gummies. The move will be the first of multiple forays into the edibles market. This announcement is particularly noteworthy, as it follows on the heels of the success of peers like PotNetwork Holding, Inc. (OTCMKTS:POTN) which has seen revenues of $14.5 million for FY 2017. This is 70 percent higher than had been estimated by management, on the success of products like is Chill CBD Gummies.
What investors need to know
We are witnessing what could just the beginning of a multi-billion dollar market. Companies like Ubiquitech Software and its HempLife Today subsidiary are leading the way towards, safe, legal, responsible use of cannabis derivatives. The demand for these products, mainly edibles like HempLife’s newly introduced CannazALL gummies, is particularly robust. That the company is already profitable and growing at a steady clip already adds to the bull case for the stock. Investors looking to get in on the ground floor of a company primed to ride this massive wave should give Ubiquitech Software strong consideration.
This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
The Elinvar Paradox: Huge Funding – Declining Sales
The business model (or at least: the original business model) of Elinvar can be compared remotely with that of the...
20 largest market caps over the years
Currently, financial companies are completely different. Since 2008 the US government has been subsidizing these financial companies with trillion dollar...
The surging TSX Venture Exchange (CDNX) and its history of booms and busts
We begin the Biden era and the stock market shot once again to new all-time highs. We look at some...
Fundstrat Global Analyst says Ethereum’s price will reach $10,500
Many assume that after a breakthrough, prices of $1,800 and more are quite possible. However, it should not be forgotten...
How to optimize your website for local search
It’s so crucial to focus your marketing efforts on getting local website traffic if you run a store-front business or...
Cannabis6 days ago
Luxembourg might soon legalize recreational cannabis
Featured7 days ago
From FinTech to Embedded Finance
Crowdfunding6 days ago
Loan and impact crowdfunding emerges stronger from the crisis
Biotech6 days ago
Jefferies unveils the list of the most promising biotech companies for 2021